The main U.S. body that evaluates preventive health measures, the U.S. Preventive Services Task Force (USPSTF), explicitly recommends against routine blood testing for genital herpes in people who have no symptoms. The reasoning comes down to a tangle of problems: the available blood tests produce an unacceptable rate of false positives, a positive result rarely changes medical management, and telling someone they carry a virus that most people never notice can cause real psychological harm with little offsetting benefit. This makes herpes unusual among sexually transmitted infections, and the logic behind the decision is more nuanced than most people expect.
The Blood Test Accuracy Problem
When clinicians screen for most infections, they rely on tests that are accurate enough that a positive result is almost certainly correct. Herpes blood tests do not clear that bar. The most widely used FDA-approved serologic test for HSV-2, called HerpeSelect, has a sensitivity of about 99% but a specificity of only about 83%. That gap matters enormously at the population level. In the general U.S. population, where roughly one in six adults carries HSV-2, the positive predictive value of HerpeSelect may be as low as 50%, meaning that about half of all positive results in a low-risk screening population are wrong.1JAMA. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement A second test, the biokit HSV-2 Rapid Test, has better specificity at around 95% but lower sensitivity, and its positive predictive value in the general population still sits around 75%.
To put this plainly: if your doctor ran a herpes blood test on every patient who walked through the door, somewhere between a quarter and half of the people told they had genital herpes would not actually have it. For a condition that carries heavy social stigma, that error rate is considered unacceptable for mass screening.
Why Confirmatory Testing Doesn’t Fully Solve the Problem
In theory, you could follow up every positive screening result with a more accurate confirmatory test. The gold standard has traditionally been the Western blot, a lab test developed at the University of Washington that is far more reliable than commercial blood tests. But even with confirmatory testing, the picture is messy. One study found that among men who tested positive on the standard ELISA blood test, about 84% were confirmed positive by Western blot, meaning roughly one in six positives was false.2PubMed. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic Among people with borderline results on the initial blood test (index values between 1.1 and 2.9), fewer than 40% were confirmed positive by Western blot.3Sexually Transmitted Diseases. Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical Setting
The Western blot itself has limited availability. For years it was offered almost exclusively through the University of Washington’s clinical virology lab, and access has been inconsistent. Building a nationwide screening program around a confirmatory test that most clinics cannot easily order is not practical public health policy, which is one more reason the whole screening cascade never got off the ground.
Most People With Herpes Don’t Know They Have It
This is one of the central paradoxes of the herpes screening debate. More than 80% of HSV-2 infections are either completely asymptomatic, mild enough that people never notice, or mistaken for something else because the classic painful ulcers never appear.4The Journal for Nurse Practitioners. Screening for Asymptomatic Genital Herpes: Is Serologic Testing Worth It? The virus can still reactivate from its dormant state and be passed to sexual partners through what is called asymptomatic shedding, and in fact the majority of new herpes transmissions come from people who have no visible lesions at the time.
This creates a genuine public health tension. On one hand, widespread unrecognized infection means the virus keeps spreading silently. On the other hand, the tools available to stop that spread after a blood test diagnosis are limited enough that identifying all those carriers may not translate into fewer infections downstream. The updated USPSTF systematic review found that the foundational case against screening rests on uncertain benefit from preventive medications combined with real harms from false-positive diagnoses, especially in populations where HSV-2 prevalence is low and false positives are therefore more common.5JAMA. Serologic Screening for Genital Herpes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
The Psychological Cost of a Positive Result
Herpes carries a stigma far out of proportion to its medical seriousness for most people. A diagnosis, even when accurate, can disrupt relationships, erode sexual confidence, and cause sustained emotional distress. Research on the psychosocial impact of being diagnosed through blood testing found that many people who tested positive for HSV-2 reported a notable decrease in quality of life, with worse outcomes among those who had less social support or higher baseline interpersonal sensitivity.6PubMed Central. The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection
The stigma can become self-reinforcing. Researchers have described a cycle in which the negative emotions triggered by a herpes diagnosis, including shame, anxiety, and fear of rejection, are linked to poorer coping and more frequent outbreaks. More frequent outbreaks, in turn, keep the stigma at the front of a person’s mind, feeding back into distress.7PubMed. The psychological impact of genital herpes stigma Now imagine inflicting that cycle on someone whose blood test was a false positive. The USPSTF weighs that harm heavily, and it is a major reason the task force has concluded that routine screening does more damage than good for the general population.
What Treatment Can and Cannot Do
If screening identified everyone with HSV-2, could we simply treat them and stop transmission? Not with the tools currently available. Daily suppressive therapy with valacyclovir does reduce viral shedding substantially, cutting the proportion of days when the virus is detectable in genital secretions by roughly 75–80%.8PubMed Central. Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes In a landmark trial, daily valacyclovir cut the rate of symptomatic HSV-2 transmission to uninfected partners by about 75% and reduced overall HSV-2 acquisition by roughly half.9PubMed. Once-daily valacyclovir to reduce the risk of transmission of genital herpes
Those numbers sound impressive, and for individual couples where one partner has herpes and the other does not, suppressive therapy is a genuinely useful option. But as a mass public health intervention, the math is less compelling. You would need to place millions of asymptomatic people on indefinite daily medication to prevent a relatively small absolute number of transmissions. Most of those people would never have had a recognized outbreak, never have transmitted the virus to anyone, and never have experienced any medical consequence from their infection. The cost, the burden of daily medication, and the side-effect exposure are difficult to justify at scale when the condition being prevented is, for most people, medically benign.10PubMed Central. Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?
When Herpes Testing Is Recommended
The recommendation against routine screening does not mean herpes testing is never appropriate. Experts have identified several situations where targeted testing makes clinical sense: people who have symptoms suggestive of herpes, people living with HIV, sexual partners of someone known to have genital herpes, and people at high risk for sexually transmitted infections who are actively trying to reduce their risk behavior.11Clinical Infectious Diseases. Recommendations for the Selective Use of Herpes Simplex Virus Type 2 Serological Tests More recently, clinical guidance has also recognized targeted screening for certain pregnant women and for people seeking sexual health evaluation in specific clinical contexts.12PubMed Central. Herpes Simplex Virus Type 2 Screening in Persons with and Without HIV: Evidence, Challenges, and Future Directions
The distinction between screening and diagnostic testing is important here. If you walk into a clinic with a sore on your genitals, your doctor should absolutely test that lesion for herpes. The issue is testing people who feel fine and have no lesions, using a blood test that looks for antibodies rather than the virus itself. That is the specific practice the USPSTF advises against for the general population.
Testing Active Lesions Is a Different Story
When someone does have a suspicious sore, the diagnostic approach is far more reliable than serologic blood testing. Modern PCR-based swab tests detect herpes DNA directly from the lesion and are significantly more sensitive than the older viral culture method. In one large comparison involving over 36,000 mucosal samples, PCR detected HSV DNA in about 12% of samples compared to only 3% for viral culture, meaning PCR caught roughly four times as many positives.13The Journal of Infectious Diseases. Polymerase Chain Reaction for Detection of Herpes Simplex Virus (HSV) DNA on Mucosal Surfaces: Comparison with HSV Isolation in Cell Culture Another clinical study found that PCR detected HSV in 57% of genital swab samples compared to 34% by culture.14Sexually Transmitted Infections. Diagnosis of genital herpes by real time PCR in routine clinical practice
PCR has largely replaced viral culture as the standard for diagnosing active herpes lesions, and it works well in neonatal settings too, where rapid and accurate diagnosis is critical.15PubMed Central. Comparison of Herpes Simplex Virus PCR with Culture for Virus Detection in Multisource Surface Swab Specimens from Neonates The point is that the medical system is not ignoring herpes or refusing to diagnose it. It has good tools for diagnosing active infection. The gap is specifically in identifying asymptomatic carriers through blood work, where the available tests are not good enough for mass screening.
The Pregnancy Question
Neonatal herpes, while rare, can be devastating. A baby infected during delivery can develop encephalitis, organ damage, or die. Given those stakes, you might expect that all pregnant women would be screened. They are not, and the reasoning is counterintuitive. The women most dangerous to their newborns are those who acquire herpes for the first time near delivery. These women are seronegative (testing negative on a blood test) at the very moment they are most infectious, which means a screening blood test earlier in pregnancy would have missed them entirely. Meanwhile, women who already have established HSV-2 infection, who would test positive, pose a much lower risk to their babies because they have already developed antibodies that provide partial protection.
One cost-effectiveness analysis found that routine antenatal herpes screening would cost over $4 million per serious neonatal outcome prevented, a figure that placed it well outside the range considered cost-effective.16PubMed. The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies A separate analysis looked at screening both pregnant women and their partners and found a more favorable ratio, with testing-plus-suppressive-therapy resulting in fewer neonatal herpes cases and fewer cesarean deliveries at a cost that fell closer to accepted thresholds per quality-adjusted life year gained.17PubMed. Cost-effectiveness of herpes simplex virus type 2 serologic testing and antiviral therapy in pregnancy A third modeling study even projected net cost savings from a screening approach designed to identify women susceptible to new acquisition, rather than those already carrying the virus.18Sexually Transmitted Infections. Projected cost-savings with herpes simplex virus screening in pregnancy: towards a new screening paradigm The economic picture, in other words, depends heavily on which question you are asking: whether the goal is to identify carriers or to identify women at risk of catching herpes for the first time during pregnancy. Despite some favorable modeling, no major professional organization currently recommends routine prenatal herpes screening.
The HSV-2 and HIV Connection
One of the strongest arguments for taking herpes more seriously at a population level is its relationship with HIV. Having HSV-2 roughly triples the risk of acquiring HIV in the general population and approximately doubles it in higher-risk groups. Among people who recently acquired HSV-2, the risk of subsequently getting HIV jumped nearly fivefold in one meta-analysis.19PubMed Central. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis In sub-Saharan Africa, where both infections are highly prevalent, the proportion of HIV infections attributable to HSV-2 has been estimated at 25–35%.20PubMed Central. Contribution of sexually transmitted infections to the sexual transmission of HIV
This led to great hope that treating HSV-2 with suppressive antiviral therapy might reduce HIV transmission. Unfortunately, large clinical trials have not shown that suppressing herpes reduces HIV acquisition or onward transmission from dually infected people, despite the fact that the therapy does lower HIV levels in both blood and genital secretions. The biological link between the two viruses is real and strong, but the available pharmacological intervention for herpes is not potent enough to exploit it as an HIV prevention strategy. This is an area where the scientific rationale for screening collides with the practical reality that screening would not currently lead to an intervention that reduces HIV spread.
Direct-to-Consumer Testing and Its Pitfalls
The rise of at-home STI test kits has added a new wrinkle. Many direct-to-consumer testing services offer herpes as part of a bundled panel, sometimes including molecular testing from urine or self-collected swabs. The American Sexually Transmitted Diseases Association has raised concerns about this practice, noting that herpes molecular testing should only be performed on specimens taken directly from lesions, not from urine or self-swabs collected at home without clinical guidance.21PubMed Central. Direct-to-Consumer Sexually Transmitted Infection Testing Services: A Position Statement from the American Sexually Transmitted Diseases Association A PCR test run on urine will not reliably detect latent HSV infection, and including it in a panel gives consumers the misleading impression that they have been thoroughly screened.
Serologic (blood-based) herpes tests offered by DTC companies carry the same accuracy problems described above, but without a clinician to explain what a positive or indeterminate result actually means, contextualize the false-positive rate, or order confirmatory testing. Someone ordering a test online at 2 a.m. and getting a positive result back with no clinical support is a recipe for the exact psychological harm that the USPSTF is trying to prevent.
Why Herpes Is So Hard to Eradicate
Part of what makes herpes resistant to the screening-and-treat approach that works for infections like chlamydia is the fundamental biology of the virus. Herpesviruses have coevolved with their hosts for millions of years, and their defining trick is latency: after the initial infection, the virus retreats into nerve cells and goes dormant, effectively hiding from the immune system.22PubMed Central. Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy No current antiviral can reach the virus in its latent state. Treatment suppresses active replication and reduces shedding, but the moment you stop taking the medication, the virus is still there.
This is fundamentally different from, say, chlamydia, where a course of antibiotics eliminates the infection entirely. With herpes, you cannot test, treat, and declare a person cured. That changes the entire calculus of screening. For chlamydia, a positive test leads to a definitive cure and prevention of complications like infertility. For herpes, a positive test leads to a lifelong diagnosis, optional suppressive medication, and a conversation about disclosure, with no possibility of clearing the virus. The cost-benefit math just does not work the same way.
Where Things Might Be Headed
The consensus against routine herpes screening is not immutable. It rests on three pillars: bad tests, limited treatment, and psychological harm. If any of those pillars shifts, the recommendation could change. Molecular diagnostics have already shown that herpes reactivation is more frequent than previously appreciated, and researchers have called for new approaches to treatment, prevention, and ultimately cure.23PubMed Central. Developments in genital herpes: progress in prevention and treatment Several vaccine candidates are in various stages of clinical development, and gene-editing approaches aimed at disrupting latent virus in nerve cells have shown early promise in animal models. A vaccine that prevented acquisition or a gene therapy that eliminated latent virus would fundamentally change the argument for screening, because a positive test would finally lead to a decisive intervention.
Better blood tests would also help. If a serologic assay could achieve positive predictive values above 95% in low-prevalence populations, the false-positive problem would shrink dramatically. Some newer assays and algorithms incorporating HSV-1 status and index-value cutoffs are already improving specificity, though none have yet reached the point where public health bodies are comfortable recommending them for population-wide use. Until one or more of these advances materializes, the screening recommendation is unlikely to budge.